Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.005
Neutral
RSI(14)
27.192
Sell
STOCH(KDJ)(9,3,3)
11.848
Oversold
ATR(14)
0.027
Low Volatility
CCI(14)
-95.288
Neutral
Williams %R
92.198
Oversold
TRIX(12,20)
-1.817
Sell
StochRSI(14)
0.000
Sell
Search
Icecure Medical Ltd
ICCMAdd to Watchlist
0.230USD
-0.011-4.65%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
18.67MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Icecure Medical Ltd
Currency: USD Updated: 2026-05-15Key Insights
Icecure Medical Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 115 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.15.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Icecure Medical Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Icecure Medical Ltd Highlights
StrengthsRisks
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.38M.
Overvalued
The company’s latest PE is -0.99, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 628.53K shares, increasing 14.54% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.150
Target Price
+792.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Icecure Medical Ltd is 6.24, ranking 157 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 911.00K, representing a year-over-year increase of 25.66%, while its net profit experienced a year-over-year increase of 19.12%.
Score
Financials
8.96
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.16
Operational Efficiency
2.84
Growth Potential
5.17
Shareholder Returns
7.08
Icecure Medical Ltd's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Icecure Medical Ltd is 7.17, ranking 116 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.99, which is 0.00% below the recent high of -0.99 and -421.22% above the recent low of -5.15.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 115/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Icecure Medical Ltd is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 3.12, with a high of 3.25 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.150
Target Price
+792.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Icecure Medical Ltd
ICCM
3
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Icecure Medical Ltd is 5.97, ranking 162 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.33 and the support level at 0.17, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.238
Sell
MA10
0.252
Sell
MA20
0.279
Sell
MA50
0.398
Sell
MA100
0.512
Sell
MA200
0.683
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Icecure Medical Ltd is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 0.77%, representing a quarter-over-quarter increase of 20.44%. The largest institutional shareholder is Ken Fisher, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Icecure Medical Ltd is 3.10, ranking 130 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.57. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.54
VaR
+7.58%
240-Day Maximum Drawdown
+80.69%
240-Day Volatility
+101.38%
Return
Best Daily Return
60 days
+10.09%
120 days
+10.09%
5 years
+734.11%
Worst Daily Return
60 days
-33.66%
120 days
-33.66%
5 years
-46.92%
Sharpe Ratio
60 days
-2.71
120 days
-2.12
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+80.69%
3 years
+85.17%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.97
3 years
-0.31
5 years
--
Skewness
240 days
-1.44
3 years
+4.26
5 years
+29.11
Volatility
Realised Volatility
240 days
+101.38%
5 years
--
Standardised True Range
240 days
+22.44%
5 years
--
Downside Risk-Adjusted Return
120 days
-211.42%
240 days
-211.42%
Maximum Daily Upside Volatility
60 days
+95.51%
Maximum Daily Downside Volatility
60 days
+102.91%
Liquidity
Average Turnover Rate
60 days
+0.99%
120 days
+0.76%
5 years
--
Turnover Deviation
20 days
-22.98%
60 days
-21.51%
120 days
-39.67%
Peer Comparison
Healthcare Equipment & Supplies
Icecure Medical Ltd
ICCM
6.04 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
